CFDE Data Portal | Search COQ3

	Label	Description
	COQ3 associations Collection (Entity type)	Associations for COQ3_associations
	COQ3 associations.tsv File (Entity type)	A file from IDG as part of the Harmonizome project
	GSE239844 6 V 10 CRIZOTINIB HUMAN DN Gene Set (Entity type)	A Gene Set from LINCS
	COQ3 Gene (Entity type)	ENSG00000132423 - coenzyme Q3, methyltransferase
	GSE248769 1 V 0 SORAFENIB HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE130401 4 V 3 TRAMETINIB HUMAN DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE212330 azacitidine 1 v 0 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE228263 FDX1 overexpression SU-DHL-4 Elesclomol 0 v 1 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE228263 elesclomol SU-DHL-4 0 v 1 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE182150 KIT LSD1 MYC inhibition 6 v 8 human dn Gene Set (Entity type)	A Gene Set from LINCS

COQ3 associations

Associations for COQ3_associations

COQ3 associations.tsv

A file from IDG as part of the Harmonizome project

GSE239844 6 V 10 CRIZOTINIB HUMAN DN

A Gene Set from LINCS

COQ3

ENSG00000132423 - coenzyme Q3, methyltransferase

GSE248769 1 V 0 SORAFENIB HUMAN UP

A Gene Set from LINCS

GSE130401 4 V 3 TRAMETINIB HUMAN DN

A Gene Set from LINCS

GSE212330 azacitidine 1 v 0 human dn

A Gene Set from LINCS

GSE228263 FDX1 overexpression SU-DHL-4 Elesclomol 0 v 1 human dn

A Gene Set from LINCS

GSE228263 elesclomol SU-DHL-4 0 v 1 human dn

A Gene Set from LINCS

GSE182150 KIT LSD1 MYC inhibition 6 v 8 human dn

A Gene Set from LINCS

DISPLAY PER PAGE

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.